Literature DB >> 32434876

CMV coinfection in treatment refractory immune checkpoint inhibitor colitis.

Kevin B Harris1, Pauline Funchain2, Brian B Baggott3.   

Abstract

As immune checkpoint inhibitors (ICIs) are increasingly used, clinicians are more frequently encountering the side effects of these therapies. ICIs have been implicated in numerous adverse effects against healthy tissues. We present a case of a patient who developed treatment refractory checkpoint inhibitor colitis. Following colonoscopy, it was discovered that this patient had cytomegalovirus (CMV) coinfection. This case report highlights the importance of undertaking an appropriate assessment, including endoscopic and histologic investigation, of patients with presumed ICI colitis. Accurately diagnosing a superimposed CMV colitis changes clinical management and can improve patient outcomes. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  gastroenterology; hepatitis and other GI infections; oncology

Mesh:

Substances:

Year:  2020        PMID: 32434876      PMCID: PMC7244273          DOI: 10.1136/bcr-2019-233519

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Immune Checkpoint Inhibitor Toxicity in 2018.

Authors:  Douglas B Johnson; Sunandana Chandra; Jeffrey A Sosman
Journal:  JAMA       Date:  2018-10-23       Impact factor: 56.272

Review 2.  Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.

Authors:  Thomas K Eigentler; Jessica C Hassel; Carola Berking; Jens Aberle; Oliver Bachmann; Viktor Grünwald; Katharina C Kähler; Carmen Loquai; Niels Reinmuth; Martin Steins; Lisa Zimmer; Anna Sendl; Ralf Gutzmer
Journal:  Cancer Treat Rev       Date:  2016-02-18       Impact factor: 12.111

Review 3.  Ulcerative Colitis and Cytomegalovirus Infection: From A to Z.

Authors:  Fadi H Mourad; Jana G Hashash; Viraj C Kariyawasam; Rupert W Leong
Journal:  J Crohns Colitis       Date:  2020-09-07       Impact factor: 9.071

4.  Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis.

Authors:  Katharina Lankes; Gheorghe Hundorfean; Thomas Harrer; Ansgar J Pommer; Abbas Agaimy; Irena Angelovska; Azadeh Tajmir-Riahi; Jonas Göhl; Gerold Schuler; Markus F Neurath; Werner Hohenberger; Lucie Heinzerling
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

Review 5.  Management of immune-related adverse events and kinetics of response with ipilimumab.

Authors:  Jeffrey S Weber; Katharina C Kähler; Axel Hauschild
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

6.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

7.  Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis.

Authors:  Cindy Franklin; Isabelle Rooms; Melanie Fiedler; Henning Reis; Laura Milsch; Saskia Herz; Elisabeth Livingstone; Lisa Zimmer; Kurt Werner Schmid; Ulf Dittmer; Dirk Schadendorf; Bastian Schilling
Journal:  Eur J Cancer       Date:  2017-10-19       Impact factor: 9.162

Review 8.  Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study.

Authors:  Ravneet Bajwa; Anmol Cheema; Taimoor Khan; Alireza Amirpour; Anju Paul; Saira Chaughtai; Shrinil Patel; Tejas Patel; Joshua Bramson; Varsha Gupta; Michael Levitt; Arif Asif; Mohammad A Hossain
Journal:  J Clin Med Res       Date:  2019-03-18

9.  Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.

Authors:  Daniel H Johnson; Chrystia M Zobniw; Van A Trinh; Junsheng Ma; Roland L Bassett; Noha Abdel-Wahab; Jaime Anderson; Jennifer E Davis; Jocelyn Joseph; Marc Uemura; Ali Noman; Hamzah Abu-Sbeih; Cassian Yee; Rodabe Amaria; Sapna Patel; Hussein Tawbi; Isabella C Glitza; Michael A Davies; Michael K Wong; Scott Woodman; Wen-Jen Hwu; Patrick Hwu; Yinghong Wang; Adi Diab
Journal:  J Immunother Cancer       Date:  2018-10-11       Impact factor: 13.751

10.  Cytomegalovirus Enterocolitis in a Patient with Refractory Immune-Related Colitis.

Authors:  Yoki Furuta; Hideaki Miyamoto; Hideaki Naoe; Miki Shimoda; Yukari Hinokuma; Tomohiro Miyamura; Azusa Miyashita; Satoshi Fukushima; Motohiko Tanaka; Yutaka Sasaki
Journal:  Case Rep Gastroenterol       Date:  2020-02-25
View more
  1 in total

1.  Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitors.

Authors:  Kavea Panneerselvam; David Szafron; Rajan N Amin; Dongguang Wei; Dongfeng Tan; Mehmet Altan; Pablo C Okhuysen; Malek Shatila; Gottumukkala Subba Raju; Anusha S Thomas; Yinghong Wang
Journal:  Ann Gastroenterol       Date:  2022-07-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.